QuorumCivic. Hidden in plain sight Get the app
Bill intelligence

Pentagon creates biotech office to fast-track military research partnerships

H.R. 6664 — To establish a Biotechnology Management Office in the Department of Defense and to provide support for the research and development of bioindustrial manufacturing processes, and for other purposes. · Filed by Joe Neguse (D-CO) · Introduced Dec 11, 2025 · Referred to committee

65%
Transparency
Typical bill: 82%
35/100
Hidden-provision risk
Typical bill: 15/100
Military Biotech Coordination & R&D…

Your members of Congress

Enter a ZIP to see where your representative and both senators stood on this bill.

Looked up on this device — your ZIP is never stored on our servers.

What it does

This bill creates a new Biotechnology Management Office within the Department of Defense, led by a senior official with biotech expertise, to coordinate military research and development of biotechnology and bioindustrial manufacturing. The office will develop long-term roadmaps, update acquisition policies, partner with industry and academia, and streamline regulatory processes for biotech adoption in the military—with a sunset date of September 30, 2030.

Why we flagged it

The bill's primary function is to establish a new DoD office tasked with coordinating biotechnology research, development, and acquisition across military and civilian partners. It is fundamentally an organizational and policy-coordination measure, not a direct appropriation or subsidy, though it authorizes use of existing R&D funds.

What the text implies

  • The office's authority to 'streamline regulatory or acquisition processes' may reduce public-health or environmental review timelines for dual-use biotech products, potentially accelerating deployment of biotechnology with limited civilian oversight.
  • Public-private partnerships and 'regionally focused innovation ecosystems' may create preferential access for private biotech firms to military R&D funding and classified research, concentrating benefits among well-connected companies.

The full analysis lists 5 implications of this text.

Who stands to gain

biotechnology companies (BIIB, Ginkgo Bioworks, Zymergen, Intrexon/Precigen, etc.); defense contractors with biotech divisions; academic research institutions with biotech programs

Correlative observation from public records — not evidence of coordination or wrongdoing, and not financial advice.
This page is the record as of today. The app tells you when it changes.
Quorum analysis of the full bill text · 119th Congress · public record